Adult Dosing

Corticosteroid-responsive dermatoses

• Apply to affected area(s) twice daily

Plaque psoriasis

• Apply thin film topically to area(s) twice daily and rub in gently; may use for up to 4 weeks

Note:

• Not for oral, ophthalmic, or intravaginal use and avoid use on the face, axilla or groin
• Treatment beyond 4 weeks is not recommended and do not use if atrophy is present at the treatment site

Pediatric Dosing

Corticosteroid-responsive dermatoses

• 10 yrs: Apply to affected area(s) bid

[Outline]

• Adult Dosing
• Pediatric Dosing

• Inflammatory hyperkeratotic dermatosis and pruritic manifestations of corticosteroid-responsive dermatoses
• Treatment of plaque psoriasis in patients 18 yrs of age (Topicort Spray)

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria have been reported in some patients with systemic absorption of topical corticosteroids
• Evaluate patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing periodically for evidence of HPA axis suppression
• Pediatric patients are more susceptible to systemic toxicity. Discontinue application and institute appropriate therapy if irritation develops
• Intracranial hypertension has been reported in pediatric patients receiving topical corticosteroids
• Appropriate antifungal or antibacterial agent should be instituted in the presence of dermatological infections
• Allergic contact dermatitis may occur, confirm by patch testing
• Local adverse reactions (eg, atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria) may likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids
• Concomitant skin infections should be treated with an appropriate antimicrobial agent and discontinue the therapy until infection has been adequately treated
• Tropical spray is flammable, avoid heat, or flame during application

Cautions: Use cautiously in

• Skin infections
• Pediatric patients

Supplemental Patient Information

• Therapy not for ophthalmic use

Pregnancy Category:C

Breastfeeding: Safety unknown. Desoximetasone has not been studied during breastfeeding. It is unlikely that short-term application of topical corticosteroids would pose a risk to the breastfed infant by passage into breastmilk. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 21 January 2011). Manufacturer advised caution when administered to a nursing woman.

• DERM: Allergic contact dermatitis, atrophy, burning, dryness, edema, folliculitis, hypersensitivity reactions, hypertrichosis, hypopigmentation, irritation, maceration, miliaria, perioral dermatitis, secondary infection, striae, acneiform eruption
• CNS: Intracranial hypertension
• ENDO: Adrenal suppression, Cushing syndrome, hyperglycemia

• Corticosteroid; suppresses normal immune response and inflammation
• Minimal systemic availability after topical application
• Metabolism: Usually metabolized in liver
• Excreted by the kidneys
• Half-life: 15-17 hrs

US Trade Name(s)

• Topicort
• Topicort LP

US Availability

desoximetasone (generic)

• CRE: 0.25%
• CRE: 0.05%
• GEL: 0.05%
• OINT: 0.25%

Topicort

• CRE: 0.25%
• GEL: 0.05%
• OINT: 0.25%
• SPRAY: 0.25%

Topicort LP

• CRE: 0.05%

Canadian Trade Name(s)

• Desoxi
• Topicort
• Topicort Mild

Canadian Availability

Desoxi

• CRE: 0.25%
• CRE: 0.05%
• GEL: 0.05%

Topicort

• CRE: 0.25%
• GEL: 0.05%
• OINT: 0.25%

Topicort Mild

• CRE: 0.05%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Dermatologic

Dermatologic Topical Agents

Steroids

Pricing data from www.DrugStore.com in U.S.A.

• Topicort 0.25 % CREA [Tube] (TARO)
  60 % = $209.98
  180 % = $574.95
• Desoximetasone 0.25 % CREA [Tube] (TARO)
  60 % = $99.6
  180 % = $258.96
• Desoximetasone 0.25 % CREA [Tube] (TARO)
  15 % = $37.99
  45 % = $113.97
• Desoximetasone 0.05 % CREA [Tube] (TARO)
  60 % = $150
  180 % = $425.99
• Desoximetasone 0.05 % CREA [Tube] (TARO)
  15 % = $49.99
  45 % = $125.97
• Topicort 0.25 % CREA [Tube] (TARO)
  15 % = $64.99
  45 % = $175.98
• Desoximetasone 0.05 % GEL [Tube] (TARO)
  60 % = $170
  180 % = $469.98
• Desoximetasone 0.05 % GEL [Tube] (TARO)
  15 % = $61.1
  45 % = $183.3
• Topicort 0.25 % OINT [Tube] (TARO)
  60 % = $259.99
  180 % = $747.95
• Desoximetasone 0.25 % OINT [Tube] (TARO)
  15 % = $72.99
  45 % = $205.97
• Desoximetasone 0.25 % OINT [Tube] (TARO)
  60 % = $228.99
  180 % = $636.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.